New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
10:03 EDTCVE, VPHM, DUK, FTI, RPM, GMCR, SYMC, PDH, CS, BSX, MLNX, CLF, RAS, MXIM, CELGOn The Fly: Analyst Upgrade Summar
Today's noteworthy upgrades include: Boston Scientific (BSX) upgraded to Outperform from Neutral at Credit Suisse... Celgene (CELG) upgraded to Buy from Neutral at BofA/Merrill... Cliffs Natural (CLF) upgraded to Buy from Hold at Deutsche Bank... Credit Suisse (CS) upgraded to Outperform from Neutral at Exane BNP Paribas... Maxim Integrated (MXIM) upgraded to Outperform from Perform at Oppenheimer... Mellanox (MLNX) upgraded to Buy from Neutral at UBS... PetroLogistics (PDH) upgraded to Buy from Neutral at Citigroup... RAIT Financial (RAS) upgraded to Outperform from Market Perform at FBR Capital... RPM (RPM) upgraded to Perform from Underperform at Oppenheimer... ViroPharma (VPHM) upgraded to Buy from Neutral at BofA/Merrill... Symantec (SYMC) upgraded to Overweight from Equal Weight at Morgan Stanley... FMC Technologies (FTI) upgraded to Overweight from Equal Weight at Morgan Stanley... Cenovus Energy (CVE) upgraded to Overweight from Neutral at JPMorgan... Green Mountain (GMCR) upgraded to Buy from Hold at Argus... Duke Energy (DUK) upgraded to Buy from Neutral at UBS.
News For BSX;CELG;CLF;CS;MXIM;MLNX;PDH;RAS;RPM;VPHM;SYMC;FTI;CVE;GMCR;DUK From The Last 14 Days
Check below for free stories on BSX;CELG;CLF;CS;MXIM;MLNX;PDH;RAS;RPM;VPHM;SYMC;FTI;CVE;GMCR;DUK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 7, 2014
07:43 EDTMXIMGoldman confirms Maxim Integrated content is in GS5
Subscribe for More Information
06:58 EDTCSDark markets could cause more harm than high-frequency trading, Reuters says
After a book by financial author Michael Lewis sparked worries that high-speed traders have been rigging the U.S. stock market, former regulators and academics say a more serious threat to investors could be the increasing amount of trading that happens outside of exchanges, reported Reuters. Top internalizers include units of KCG Holdings (KCG), Citadel, UBS (UBS), and Citigroup (C). Dark pool operators include Credit Suisse (CS) and Morgan Stanley (MS). In an attempt to earn back some of the retail orders, exchanges such as IntercontinentalExchange Group's (ICE) New York Stock Exchange, Nasdaq (NDAQ), and BATS Global Markets, have allowed brokerages to place dark pool-style orders on their platforms, with the trade hidden until after it is executed. Reference Link
06:28 EDTCSNew York launches probe of Credit Suisse, NY Times says
Subscribe for More Information
April 4, 2014
16:30 EDTSYMCOn The Fly: Closing Wrap
Subscribe for More Information
15:22 EDTSYMCSymantec calls active on eyed by activists, interviews advisors
Subscribe for More Information
14:59 EDTSYMCSymantec eyed by activists, interviews advisors, Reuters says
Subscribe for More Information
14:37 EDTSYMCSymantec hiring bank for strategic advice, Reuters says
Symantec is being examined as a potential target by large activist funds, according to Reuters.
10:45 EDTCELGMylan rises despite Meda rejecting takeover offer
Mylan (MYL) shares are higher this morning following a Financial Times report of its desire to buy Swedish rival Meda. Subsequent to the story being published, Meda confirmed it had been in talks with Mylan but rejected the company's takeover offer. WHAT'S NEW: The Financial Times reported that Mylan was considering buying Meda, a Swedish drugmaker, in a deal that would create a $23B+ pharmaceuticals business. Mylan reportedly hired advisers to put a deal together for Meda, and though the value of a deal was not noted, sources said Mylan was likely to pay a "significant" premium to Meda's market value, which was $4.5B at the end of trading on Thursday. Mylan's market value currently stands at $18.5B. A combination of the drugmakers would create a company with annual revenues of around $9B, the FT said, noting that would be half the size of generic drug rival Teva (TEVA). WHAT'S NOTABLE: Meda's board of directors confirmed that it was contacted by Mylan regarding a proposal to merge the companies, but the board decided to reject the proposal. Meda said all discussions between the company and Mylan have been terminated "without further actions." ANALYST REACTION: Citigroup upgraded Mylan to Buy from Neutral and raised its price target on the stock to $61 from $52 this morning. The firm cited potential operational and tax benefits from an acquisition of Meda, stating that in addition to expanding Mylan's geographic presence, the deal would increase its presence in specialty, OTC and branded generics. OTHER NEWS: Mylan sued Celgene (CELG) to block that company's efforts to keep generic versions of Revlimid and Thalomid off the market, Reuters reported. PRICE ACTION: Mylan shares are up $2.98, or 5.98%, to $52.84 in mid-morning trading.
10:17 EDTGMCRCoke investment in Keurig cuts short interest but also M&A talk, Bloomberg says
Subscribe for More Information
06:49 EDTCELGMylan sues Celgene for blocking Thalomid, Revlimid generics, Reuters says
Subscribe for More Information
06:26 EDTCSRoyal Bank of Scotland names Ewen Stevenson as CFO
Subscribe for More Information
05:49 EDTGMCRStocks with implied volatility movement; GMCR AMAT
Stocks with implied volatility movement; Keurig Green Mountain (GMCR) 47, Applied Materials (AMAT) 33 according to iVolatility.
April 3, 2014
12:10 EDTRPMOn The Fly: Midday Wrap
Stocks on Wall Street began the session in positive territory, with the Dow notching a new all-time high, but had slid into negative ground at midday. The Nasdaq is the biggest loser, as it is down more than 0.6%, while the Dow and Nasdaq are just slightly below the flat line. ECONOMIC EVENTS: In the U.S., initial jobless claims rose to 326K in the week ended March 29, versus the expected 319K claims. The trade deficit widened to $42.3B in February from a revised $39.3B deficit in January. ISM's non-manufacturing PMI rose 1.5 points to 53.1 in March, though that was a bit below the 53.5 forecast of economists. In Europe, the ECB maintained its current rates despite the ongoing debate over disinflationary forces posing an increasing risk. In Asia, China's State Council announced a stimulus package for new railways and subways, low-income housing and tax breaks for small business, but most of the measures were part of the government's previously communicated annual economic work plan. COMPANY NEWS: Shares of Barnes & Noble (BKS) are declining after Liberty Media (LMCA) announced a deal to reduce its stake in the bookseller. Liberty said it has sold the majority of its shares to institutional buyers and will retain approximately 10% of its initial investment, which has been reported to equate to a roughly 2% stake in Barnes & Noble. B&N Chairman Leonard Riggio said that Liberty’s reduced ownership gives the company greater flexibility to pursue various strategic options, but shares of B&N slid 13% following the announcement... Citigroup (C) shares fell almost 2% after The New York Times said the federal government has started a criminal investigation into alleged fraud involving Citi's Banamex unit in Mexico. Also of note, research firm Sterne Agee downgraded the stock to Neutral, citing the Fed's refusal to approve the bank's capital plan, along with its slowing earnings growth and lack of catalysts, as reasons for the downgrade. MAJOR MOVERS: Among the notable gainers was Amyris (AMRS), which rose 8% after announcing that it is entering into a strain engineering research and development agreement with chemical giant BASF (BASFY). Also higher was chemical, paint, and coating maker RPM (RPM), which gained 4% and hit a fresh 52-week high earlier in the session after the company raised its fiscal 2014 profit outlook. Among the noteworthy losers was Liquidity Services (LQDT), which slid another 12% after the company confirmed it's withdrawal from auction bidding for a U.S. Department of Defense contract and said it will need to reset its adjusted earnings expectations. Also lower were shares of weight-loss drug maker VIVUS (VVUS), which fell nearly 8% following a downgrade to Underweight at Piper Jaffray. INDEXES: Near midday, the Dow was down 16.31, or 0.1%, to 16,556.69, the Nasdaq was down 26.65, or 0.62%, to 4,249.81, and the S&P 500 was down 3.48, or 0.18%, to 1,887.42.
12:00 EDTRPMRPM rises 4.4%
Subscribe for More Information
11:19 EDTRPMRPM hits 52-week high after raising full year profit outlook
Shares of specialty chemical, paint, and coating maker RPM (RPM) are rallying after the company raised its fiscal 2014 profit outlook. WHAT'S NEW: This morning, RPM reported third quarter earnings per share of 12c and revenue of $863.4M, compared to expectations of 9c and $877.67M, respectively. RPM raised its FY14 EPS view to $2.10-$2.15 from $2.05-$2.10, compared to consensus of $2.11. It also forecast FY14 industrial sales growth of 4%-6% and consumer sales growth of 8%-10%. The company cited stronger than anticipated leverage in its industrial segment, resulting from solid performance in Europe and businesses serving U.S. construction markets, as the reason for the improved outlook. PRICE ACTION: In late morning trading, RPM rose $2.03, or 4.8%, to $44.20 on heavy trading volume. Earlier in the session, the stock hit a fresh 52-week high of $45.47. Including today's advance, the stock is up approximately 43% over the past twelve months. OTHERS TO WATCH: Other companies in the paint and coatings space include PPG Industries (PPG), Valspar (VAL), and Sherwin Williams (SHW).
10:00 EDTRPMRPM rises 7%
Subscribe for More Information
07:33 EDTRPMRPM raises FY14 EPS to $2.10-$2.15 from $2.05-$2.10, consensus $2.11
Sees improving momentum in industrial segment, combined with pent-up demand in consumer segment as result of severe winter weather in North America. Sees FY14 industrial sales growth of 4%-6% and consumer sales growth of 8%-10%.
07:32 EDTRPMRPM reports Q3 EPS 12c, consensus 9c
Subscribe for More Information
06:28 EDTCELGAtopic dermatitis could bring upside to Regeneron, Celgene, says Citigroup
Citigroup believes Regeneron's (REGN) dupilumab and Celgene's (CELG) Otezla for atopic dermatitis are being overlooked by investors and could provide upside for both names. Citi believes both drugs have good efficacy but adds that dupilumab is more advanced. The firm has a Buy rating on both stocks.
05:47 EDTCSCredit Suisse announces charge of CHF 468M for litigation provision
Credit Suisse said its preliminary results for 2013 were updated to reflect an additional after-tax charge of CHF 468M, primarily due to an increase in the litigation provision relating to the ongoing United States Department of Justice investigation into the U.S. tax-related matter. As a result, Credit Suisse reported a net loss of CHF 476M for Q4. For the full year 2013, reported core results pre-tax income was CHF 3.5B, compared to CHF 1.89B in 2012, and reported 2013 net income attributable to shareholders was CHF 2.3B, compared to CHF 1.35B in 2012. Credit Suisse’s Look-through Total Capital ratio was 15.7%, Look-through Basel III CET1 ratio was 10.0%, and Basel III CET1 ratio was 15.7% as of the end of 2013.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use